| Literature DB >> 34554826 |
Kathryn M Hastie1, Haoyang Li1, Daniel Bedinger2, Sharon L Schendel1, S Moses Dennison3, Kan Li3, Vamseedhar Rayaprolu1, Xiaoying Yu1, Colin Mann1, Michelle Zandonatti1, Ruben Diaz Avalos1, Dawid Zyla1, Tierra Buck1, Sean Hui1, Kelly Shaffer1, Chitra Hariharan1, Jieyun Yin1, Eduardo Olmedillas1, Adrian Enriquez1, Diptiben Parekh1, Milite Abraha3, Elizabeth Feeney3, Gillian Q Horn3, Yoann Aldon4, Hanif Ali5, Sanja Aracic6, Ronald R Cobb7, Ross S Federman8, Joseph M Fernandez9, Jacob Glanville10, Robin Green8, Gevorg Grigoryan8, Ana G Lujan Hernandez11, David D Ho12, Kuan-Ying A Huang13, John Ingraham8, Weidong Jiang14, Paul Kellam15,16, Cheolmin Kim17, Minsoo Kim17, Hyeong Mi Kim17, Chao Kong18, Shelly J Krebs19, Fei Lan9,20, Guojun Lang18, Sooyoung Lee17, Cheuk Lun Leung8, Junli Liu14, Yanan Lu9,21, Anna MacCamy22, Andrew T McGuire22, Anne L Palser15, Terence H Rabbitts5,23, Zahra Rikhtegaran Tehrani24, Mohammad M Sajadi24, Rogier W Sanders4, Aaron K Sato11, Liang Schweizer25, Jimin Seo17, Bingqing Shen25, Jonne L Snitselaar4, Leonidas Stamatatos22, Yongcong Tan18, Milan T Tomic26, Marit J van Gils4, Sawsan Youssef10, Jian Yu12, Tom Z Yuan11, Qian Zhang25, Bjoern Peters1,27, Georgia D Tomaras3, Timothy Germann2, Erica Ollmann Saphire1,27.
Abstract
Antibody-based therapeutics and vaccines are essential to combat COVID-19 morbidity and mortality after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Multiple mutations in SARS-CoV-2 that could impair antibody defenses propagated in human-to-human transmission and spillover or spillback events between humans and animals. To develop prevention and therapeutic strategies, we formed an international consortium to map the epitope landscape on the SARS-CoV-2 spike protein, defining and structurally illustrating seven receptor binding domain (RBD)–directed antibody communities with distinct footprints and competition profiles. Pseudovirion-based neutralization assays reveal spike mutations, individually and clustered together in variants, that affect antibody function among the communities. Key classes of RBD-targeted antibodies maintain neutralization activity against these emerging SARS-CoV-2 variants. These results provide a framework for selecting antibody treatment cocktails and understanding how viral variants might affect antibody therapeutic efficacy.Entities:
Mesh：
Substances：
Year: 2021 PMID： 34554826 PMCID： PMC9302186 DOI： 10.1126/science.abh2315
Source DB: PubMed Journal: Science ISSN： 0036-8075 Impact factor: 63.714